Related Experiment Videos
Tuberculosis due to Mycobacterium kansasii.
Australian and New Zealand Journal of Medicine
|February 1, 1977
Summary
Tuberculosis caused by Mycobacterium kansasii presents like Mycobacterium tuberculosis but requires different drug treatments. This infection is resistant to standard tuberculosis drugs but responds to ethionamide and cycloserine.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Pulmonology
Background:
- Tuberculosis (TB) remains a significant global health challenge.
- Mycobacterium tuberculosis is the primary causative agent of TB.
- Emerging or less common mycobacterial species can cause TB-like illness.
Observation:
- Eighteen cases of tuberculosis attributed to Mycobacterium kansasii were identified.
- Cases were geographically clustered in Western Australia (11) and Queensland (7).
- Clinical presentation, radiographic findings, and histological features mimicked classic tuberculosis.
Findings:
- Mycobacterium kansasii demonstrated resistance to first-line anti-TB drugs: streptomycin, para-aminosalicylic acid (PAS), and isoniazid.
- The pathogen was sensitive to ethionamide and cycloserine.
- Sensitivity to rifampicin and ethambutol was observed in most cases.
Implications:
- This highlights the importance of antimicrobial susceptibility testing for atypical mycobacterial infections.
- Treatment regimens for Mycobacterium kansasii TB must differ from standard M. tuberculosis protocols.
- Effective management requires knowledge of drug resistance patterns for accurate therapeutic selection.